The NHS's spending watchdog acted unlawfully when it decided to restrict access to drugs that could help thousands of older women with the bone-thinning disease osteoporosis, the high court ruled today. A judge ruled that the National Institute for Health and Clinical Excellence (Nice) wrongly failed to disclose the economic reasoning behind a decision in October to restrict the supply of strontium ranelate, a drug manufactured by Servier laboratories under the brand name Protelos.
Debbie Purdy, who wants her husband to accompany her to Switzerland for an assisted suicide without fear of prosecution, took her case to the United Kingdom’s highest court, the House of Lords, for a final appeal this week. Ms Purdy, who has progressive multiple sclerosis, scored an important victory on the first day of the two day hearing, when the director of public prosecutions, Keir Starmer, conceded that article 8 of the European Convention on Human Rights, the right to respect for private life, applies to cases like hers.
A couple have spoken of their shock after an IVF clinic mix-up led to their last embryo being wrongly implanted into another patient. They were further angered when it emerged the other woman was given the morning-after pill. The couple from Bridgend won their case for damages after the mistake at Cardiff's University Hospital of Wales. Cardiff and Vale NHS Trust apologised "unreservedly" for the error and said it had improved checking procedures. The trust admitted gross failures in care and has also agreed to pay an undisclosed settlement to the couple.
A trainee teacher with primary refractory Hodgkin’s lymphoma has launched a High Court action against her primary care trust, NHS Surrey, which has refused to pay for her treatment with an unlicensed drug. Philippa Bigham, aged 28, from Frimley, Surrey, has been given a prognosis of two years’ survival without a bone marrow transplantation. But her medical team at the Royal Free Hospital in London want her to have treatment with radiolabelled basiliximab, a monoclonal antibody conjugated with radioactive iodine and also known as CHT-25, before she has the transplantation. The primary care trust has refused to pay for the drug, which costs £3000 ({euro}3500; $4900) for a course of treatment. Basiliximab is licensed in the United Kingdom for use in renal transplant rejection but the radiolabelled version is not yet licensed.
The Supreme Court in the US state of Montana is due to begin hearing arguments to decide if severely ill people there have the constitutional right to ask their doctor to help them die. A lower court judgement last December decided that they did, but now the state of Montana is trying to have that ruling overturned.